Joe Y Chang1, Suresh Senan2, Marinus A Paul3, Reza J Mehran4, Alexander V Louie2, Peter Balter5, Harry J M Groen6, Stephen E McRae7, Joachim Widder8, Lei Feng9, Ben E E M van den Borne10, Mark F Munsell9, Coen Hurkmans11, Donald A Berry9, Erik van Werkhoven12, John J Kresl13, Anne-Marie Dingemans14, Omar Dawood15, Cornelis J A Haasbeek2, Larry S Carpenter16, Katrien De Jaeger11, Ritsuko Komaki17, Ben J Slotman2, Egbert F Smit18, Jack A Roth4. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jychang@mdanderson.org. 2. Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands. 3. Department of Cardiothoracic Surgery, VU University Medical Center, Amsterdam, Netherlands. 4. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, Netherlands. 7. Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8. Department of Radiation Oncology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands. 9. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10. Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, Netherlands. 11. Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands. 12. Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands. 13. Phoenix CyberKnife and Radiation Oncology Center, Phoenix, AZ, USA. 14. Department of Pulmonary Diseases, Maastricht University Medical Center, Netherlands. 15. Kona Medical, Bellevue, WA, USA. 16. Department of Radiation Oncology, CHI St Luke's Health, Houston, TX, USA. 17. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 18. Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, Netherlands.
Abstract
BACKGROUND: The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stageI NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. METHODS:Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a (<4 cm), N0M0, operable NSCLC. Patients were randomly assigned in a 1:1 ratio to SABR or lobectomy with mediastinal lymph node dissection or sampling. We did a pooled analysis in the intention-to-treat population using overall survival as the primary endpoint. Both trials are registered with ClinicalTrials.gov (STARS: NCT00840749; ROSEL: NCT00687986). FINDINGS:58 patients were enrolled and randomly assigned (31 to SABR and 27 to surgery). Median follow-up was 40·2 months (IQR 23·0-47·3) for the SABR group and 35·4 months (18·9-40·7) for the surgery group. Six patients in the surgery group died compared with one patient in the SABR group. Estimated overall survival at 3 years was 95% (95% CI 85-100) in the SABR group compared with 79% (64-97) in the surgery group (hazard ratio [HR] 0·14 [95% CI 0·017-1·190], log-rank p=0·037). Recurrence-free survival at 3 years was 86% (95% CI 74-100) in the SABR group and 80% (65-97) in the surgery group (HR 0·69 [95% CI 0·21-2·29], log-rank p=0·54). In the surgery group, one patient had regional nodal recurrence and two had distant metastases; in the SABR group, one patient had local recurrence, four had regional nodal recurrence, and one had distant metastases. Three (10%) patients in the SABR group had grade 3 treatment-related adverse events (three [10%] chest wall pain, two [6%] dyspnoea or cough, and one [3%] fatigue and rib fracture). No patients given SABR had grade 4 events or treatment-related death. In the surgery group, one (4%) patient died of surgical complications and 12 (44%) patients had grade 3-4 treatment-related adverse events. Grade 3 events occurring in more than one patient in the surgery group were dyspnoea (four [15%] patients), chest pain (four [15%] patients), and lung infections (two [7%]). INTERPRETATION:SABR could be an option for treating operable stage I NSCLC. Because of the small patient sample size and short follow-up, additional randomised studies comparing SABR with surgery in operable patients are warranted. FUNDING: Accuray Inc, Netherlands Organisation for Health Research and Development, NCI Cancer Center Support, NCI Clinical and Translational Science Award.
RCT Entities:
BACKGROUND: The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. METHODS: Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a (<4 cm), N0M0, operable NSCLC. Patients were randomly assigned in a 1:1 ratio to SABR or lobectomy with mediastinal lymph node dissection or sampling. We did a pooled analysis in the intention-to-treat population using overall survival as the primary endpoint. Both trials are registered with ClinicalTrials.gov (STARS: NCT00840749; ROSEL: NCT00687986). FINDINGS: 58 patients were enrolled and randomly assigned (31 to SABR and 27 to surgery). Median follow-up was 40·2 months (IQR 23·0-47·3) for the SABR group and 35·4 months (18·9-40·7) for the surgery group. Six patients in the surgery group died compared with one patient in the SABR group. Estimated overall survival at 3 years was 95% (95% CI 85-100) in the SABR group compared with 79% (64-97) in the surgery group (hazard ratio [HR] 0·14 [95% CI 0·017-1·190], log-rank p=0·037). Recurrence-free survival at 3 years was 86% (95% CI 74-100) in the SABR group and 80% (65-97) in the surgery group (HR 0·69 [95% CI 0·21-2·29], log-rank p=0·54). In the surgery group, one patient had regional nodal recurrence and two had distant metastases; in the SABR group, one patient had local recurrence, four had regional nodal recurrence, and one had distant metastases. Three (10%) patients in the SABR group had grade 3 treatment-related adverse events (three [10%] chest wall pain, two [6%] dyspnoea or cough, and one [3%] fatigue and rib fracture). No patients given SABR had grade 4 events or treatment-related death. In the surgery group, one (4%) patient died of surgical complications and 12 (44%) patients had grade 3-4 treatment-related adverse events. Grade 3 events occurring in more than one patient in the surgery group were dyspnoea (four [15%] patients), chest pain (four [15%] patients), and lung infections (two [7%]). INTERPRETATION:SABR could be an option for treating operable stage I NSCLC. Because of the small patient sample size and short follow-up, additional randomised studies comparing SABR with surgery in operable patients are warranted. FUNDING: Accuray Inc, Netherlands Organisation for Health Research and Development, NCI Cancer Center Support, NCI Clinical and Translational Science Award.
Authors: Subroto Paul; Art Sedrakyan; Ya-Lin Chiu; Abu Nasar; Jeffrey L Port; Paul C Lee; Brendon M Stiles; Nasser K Altorki Journal: Eur J Cardiothorac Surg Date: 2012-07-22 Impact factor: 4.191
Authors: Shervin M Shirvani; Jing Jiang; Joe Y Chang; James Welsh; Anna Likhacheva; Thomas A Buchholz; Stephen G Swisher; Benjamin D Smith Journal: JAMA Surg Date: 2014-12 Impact factor: 14.766
Authors: N E Verstegen; J W A Oosterhuis; D A Palma; G Rodrigues; F J Lagerwaard; A van der Elst; R Mollema; W F van Tets; A Warner; J J A Joosten; M I Amir; C J A Haasbeek; E F Smit; B J Slotman; S Senan Journal: Ann Oncol Date: 2013-02-20 Impact factor: 32.976
Authors: Mark S Allen; Gail E Darling; Taine T V Pechet; John D Mitchell; James E Herndon; Rodney J Landreneau; Richard I Inculet; David R Jones; Bryan F Meyers; David H Harpole; Joe B Putnam; Valerie W Rusch Journal: Ann Thorac Surg Date: 2006-03 Impact factor: 4.330
Authors: Feiran Lou; James Huang; Camelia S Sima; Joseph Dycoco; Valerie Rusch; Peter B Bach Journal: J Thorac Cardiovasc Surg Date: 2012-11-03 Impact factor: 5.209
Authors: Joe Y Chang; Hui Liu; Peter Balter; Ritsuko Komaki; Zhongxing Liao; James Welsh; Reza J Mehran; Jack A Roth; Stephen G Swisher Journal: Radiat Oncol Date: 2012-09-10 Impact factor: 3.481
Authors: Teodora-Cristiana Dumitra; Juan-Carlos Molina; Jack Mouhanna; Ioana Nicolau; Stephane Renaud; Ludovic Aubin; Aya Siblini; David Mulder; Lorenzo Ferri; Jonathan Spicer Journal: Can J Surg Date: 2020-07-31 Impact factor: 2.089
Authors: Nichole T Tanner; Lin Dai; Brett C Bade; Mulugeta Gebregziabher; Gerard A Silvestri Journal: Am J Respir Crit Care Med Date: 2017-09-01 Impact factor: 21.405
Authors: Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi Tazehmahalleh; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Theodor Eich; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2017-05-31 Impact factor: 3.621
Authors: Christopher Cao; Daniel Wang; Caroline Chung; David Tian; Andreas Rimner; James Huang; David R Jones Journal: J Thorac Cardiovasc Surg Date: 2018-09-15 Impact factor: 5.209